July 29, 2019

Abdi ibrahim to recruit 270 more employees

Enjoying uninterrupted market leadership in the Turkish pharmaceutical industry for the last 17 years, Abdi İbrahim continues its multi-faceted contribution to the Turkish economy with a new employment package. Having increased its production capacity through completed and ongoing investments at its Esenyurt Production Complex, Abdi İbrahim has announced that it will recruit 270 more individuals for its medical representative team -its biggest forte in the field-, and for the position of product manager. Abdi İbrahim Chairman Nezih Barut has stated, "Courage, ambition and responsibility are the values that describe Abdi İbrahim best, and they shed light on our path under all circumstances. We consider investment, production and especially employment not only as priorities for growing our business, but rather as our responsibility towards our nation and the industry. Our field team of over 2 thousand individuals working hard to improve living standards across every corner of Turkey has played a huge role in Abdi Ibrahim's 17-year leadership in the market. We are very much excited that we will soon expand their ranks further through our new recruitment program."

Active in the Turkish pharmaceutical industry for 107 years, Abdi İbrahim has been reinforcing its clout in the sector day after day with continuous investments in Turkey and abroad, and has now announced that it will provide employment to 270 more individuals in the next two months. Abdi İbrahim Chairman Nezih Barut has indicated that they have never lost their focus on investment and production despite the shifts in economic juncture. Pointing to the ongoing TL 1 billion 275 million investment at the Abdi İbrahim facilities in Esenyurt, Nezih Barut has indicated that the company is determined to grow further with new products and especially new manufacturing deals inked with global pharmaceutical giants in 2019.

Nezih Barut: ‘Our nation's priority is our priority’

Underlining that for over a century Abdi Ibrahim has embraced Turkey's priorities as its own, Nezih Barut has indicated that youth employment is an issue of major importance in Turkey: "66 percent of Abdi İbrahim employees belong to the Generation Y. Thanks to their young and dynamic outlook, we maintain our leadership as a deep-rooted, yet future-oriented company. Our field team of over 2 thousand individuals working hard to improve living standards across every corner of Turkey has played a huge role in Abdi Ibrahim's 17-year leadership in the market. We are very much excited that, with our new recruitment package, we will soon be recruiting 270 more colleagues -250 of whom Medical Representatives- for the Abdi İbrahim family." Stressing that courage, ambition and responsibility are values that describe Abdi İbrahim best, Barut has emphasized, "We consider investment, production and especially employment not only as priorities for growing our business, but rather as our responsibility towards our nation and the industry. Our new recruitment program is a new and strong reflection of this approach."

Nezih Barut: ‘We will double our production capacity’’

Emphasizing that the creation of such additional employment is a result of their planned and continuous investment power and ambitious growth targets, Nezih Barut has indicated that in 2019, they have focused not only on new products but also new manufacturing services. Stating that Abdi İbrahim's ongoing TL 900 million Sterile Injectable and Oncology Production Facility will be completed in 2021 and that the TL 375 million Sterile Ophthalmology and Sterile Inhalation Production Facility investment will be completed by end-2019, Nezih Barut has announced that these investments will nearly double their overall manufacturing capacity.

Nezih Barut: “We will continue investments and partnerships that uphold Turkey's goal of becoming a regional power in pharmaceuticals.”

Barut has underlined that, in addition to these ongoing investments, they have focused on manufacturing services following the inauguration in 2018 of AbdiBio, Turkey's largest biotechnology facilities: "Our manufacturing services, which we have been providing for many years, have entered a distinct and intense phase upon the launch of the Pharmaceutical Localization scheme. We have been signing a series of manufacturing agreements with global pharmaceutical giants. For example, under the scope of our agreement with GSK, we will produce sterile inhalation products (nebul) in the form of BFS at our Sterile Inhalation Production Facility. We have also become Allergan's manufacturing partner in Turkey. The ophthalmological eye drops that we will produce at our Sterile Ophthalmology Production Facility are of huge importance since they constitute Allergan's only production outside of its own facilities. Through such agreements, we are very much pleased to reinforce the trust in our company of international pharmaceutical companies, and to obtain rapid returns from our investments. We will continue such investments and partnerships that uphold Turkey's goal of becoming a regional power in pharmaceuticals.”